SLC5A2 and type 2 diabetes mellitus: Sodium–glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) are highly selective, effective, and generally well-tolerated anti-hyperglycaemic agents approved for treating adults with type 2 diabetes mellitus.